U.S. Food and Drug Administration Approves CSL's ANDEMBRY® (garadacimab-gxii), the Only Prophylactic Hereditary Angioedema (HAE) Treatment Targeting Factor XIIa with Once-Monthly Dosing for All ...

ANDEMBRY inhibits the top of the HAE cascade by targeting factor XIIa and provides sustained protection from attacks Once-monthly dosing reduced HAE attacks by a median of more than 99 percent and ...

CSL Behring’s new facility in Broadmeadows, Victoria, has been named the 2025 Facility of the Year by the International Society for Pharmaceutical Engineering (ISPE), in the Pharma 4.0 category. The ...

CSL Seqirus to provide pandemic influenza vaccine to support 17 EU and EEA countries and the EU Commission in the event of a pandemic declaration. The decision by the Health Emergency Preparedness ...

ST. GALLEN, Switzerland and SAN DIEGO, April 29, 2025 /PRNewswire/ -- CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) are pleased to announce that the European Commission has approved the ...

ANDEMBRY® received manufacturing and marketing approval in Japan on February 20, 2025, for the prevention of acute attacks in hereditary angioedema (HAE) ANDEMBRY® is the first-in-class monoclonal ...

- KOSTAIVE represents a significant advancement in vaccine technology, demonstrating superior immunogenicity and antibody persistence for up to 12 months post-vaccination compared to conventional ...

Melbourne, 4 March 2025 – CSL Seqirus and Esperion Therapeutics have today announced the signing of an exclusive license and distribution agreement to commercialize Nexletol® (bempedoic acid) ...

ANDEMBRY® is the first and only once-monthly treatment targeting factor XIIa to prevent recurrent attacks in HAE patients. The approval marks the fifth regulatory approval of ANDEMBRY, reinforcing CSL ...

ANDEMBRY ® is a first-in-class monoclonal antibody treatment that inhibits activated Factor XII (FXIIa), the initiating factor in the HAE pathway, and offers the first pre-filled pen presentation ...

"ANDEMBRY is a significant advancement in the management of hereditary angioedema, offering people living with this life-threatening condition long-term control over their disease with a ...

CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B ...